Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying 89Zr-TLX250, a diagnostic imaging agent, to detect clear cell renal cell carcinoma ccRCC in Chinese patients with indeterminate renal masses. This Phase 3, open-label, single-arm study aims to confirm the safety, tolerability, sensitivity, and specificity of 89Zr-TLX250 PETCT imaging. The study supports prior ZIRCON trial data and involves adult patients scheduled for partial or total nephrectomy as part of their standard care. Participants will receive a single intravenous dose of 37 MBq of 89Zr-TLX250 containing 10 mg of girentuximab. Imaging of the abdomen using PETCT will be performed 5 days post-administration, with possible whole-body imaging if widespread disease is suspected. Nephrectomy will occur any time after imaging but within 90 days. Histological analysis of tumor samples will confirm diagnosis. The study includes approximately seven visits over 4 to 6 months. Assessments include baseline exams, PETCT imaging, surgery, and follow-up visits. Imaging and histological data will be centrally analyzed to evaluate diagnostic accuracy. Safety and tolerability will be monitored throughout. The study is expected to last about 12 months with 4 months of follow-up per participant.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and cellular behavior of CT1190B cells in patients with relapsed or refractory large B-cell lymphoma LBCL. This Phase III clinical trial aims to find the right dose and understand how the treatment acts in the body. The study focuses on patients who have received at least two prior treatments and whose cancer has returned or not responded. Participants receive CT1190B through intravenous infusion. The trial is a single-arm, open-label study without a placebo group. The treatment period includes monitoring for up to 12 months after infusion to assess adverse events and treatment responses. Researchers will evaluate multiple outcomes including response rates, duration of response, progression-free survival, overall survival, and various cellular pharmacokinetics and immune parameters. During the study, participants will undergo regular assessments including scans to measure tumor size, laboratory tests, and monitoring of side effects. Researchers will track safety events such as treatment-related adverse events and serious adverse events for up to 12 months. Long-term outcomes like progression-free and overall survival will be followed for up to 180 months. Participants must be willing and able to complete all trial procedures and follow-up visits throughout the study duration.
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.
Actively Recruiting
Researchers are evaluating the safety, tolerability, drug levels, and preliminary antitumor activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer NSCLC that have a KRAS p.G12C mutation combined with an STK11 co-mutation and wild-type KEAP1. This open-label study includes participants who are either treatment-nave or have had at least one prior therapy for advanced disease. The study consists of a dose escalation phase where JAB-21822 is given orally as a monotherapy to determine the maximum tolerated dose and recommended phase 2 dose. This is followed by two dose expansion parts one with participants previously untreated and another with participants who received at least one prior systemic therapy. The treatment is administered continuously in 21-day cycles, with safety and clinical activity monitored throughout. Participants will be closely monitored with assessments including adverse event tracking, pharmacokinetics drug levels in plasma, and tumor response evaluations according to RECIST criteria. The primary outcomes include dose limiting toxicities in the first cycle, objective response rate during the dose expansion, and longer-term safety over up to three years. The total study duration extends up to three years, allowing detailed evaluation of treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 tablets in patients with relapsed or refractory hematologic malignancies, including B-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. This Phase I trial aims to determine the maximum tolerated dose and recommended phase 2 dose of XS-04, while also exploring metabolic transformation, biomarker associations, and the impact of food on the drugs pharmacokinetics. Participants receive XS-04 tablets orally twice daily in 28-day treatment cycles. The study includes a dose escalation phase with varying doses from 1 mg to 160 mg per day and a dose expansion phase using the recommended dose identified earlier. Dose adjustments may be made based on safety, efficacy, and pharmacokinetic data collected during the trial. During the study, participants undergo safety and tolerability assessments, pharmacokinetic sampling after single and multiple doses, and evaluations of treatment-related adverse events. Researchers also monitor pharmacodynamic biomarkers and exposure-effect relationships. The study follows participants for up to 24 months to determine dose-limiting toxicities and recommended dosing levels, with safety monitoring continuing up to 30 days after the last dose.
Actively Recruiting
Researchers are evaluating the safety and antitumor activity of the drug INV-9956 in adult men with advanced metastatic castration resistant prostate cancer. This study is conducted in two parts Phase 1 focuses on finding the right dose and assessing safety, while Phase 2 aims to confirm safety and explore how well the drug works in patients with different androgen receptor gene statuses. Participants receive INV-9956 along with dexamethasone and fludrocortisone acetate. In Phase 1, dose levels are gradually increased using a careful monitoring process to find the maximum tolerated dose and recommended dose range. Phase 2 includes two groups one with mutated androgen receptor cancer and one with wild-type androgen receptor cancer, to further evaluate the drugs effects. During the study, participants will undergo various assessments including safety evaluations, blood tests for drug concentration and hormone levels, and imaging to track cancer progression. The main outcomes measured are maximum tolerated dose, radiographic progression-free survival, and overall response rate over 12 months. The study also monitors side effects and drug behavior in the body to better understand treatment effects and safety.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the safety and pharmacokinetics of Hydronidone capsules, a pyridinone-based drug, in patients with renal insufficiency and healthy individuals. Hydronidone has shown promise in treating liver fibrosis in chronic hepatitis B through earlier clinical trials. This study aims to understand how the drug behaves in the body of patients with varying degrees of kidney dysfunction to guide safe medication use. Participants will receive a single oral dose of 90 mg Hydronidone capsules on an empty stomach on the morning of Day 1. The study includes four groups healthy volunteers, and patients with mild, moderate, or severe renal insufficiency. All participants take the medication once, and their responses are monitored. During the trial, participants will undergo blood and urine tests to measure drug and metabolite concentrations over 48 hours. Safety assessments include ultrasounds of various organs and electrocardiograms performed 72 hours after dosing. Researchers will track any adverse events and evaluate the bodys handling of the drug to ensure safety and understand drug behavior in people with kidney issues. Participation lasts a few days with close monitoring.
Actively Recruiting
Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.
Actively Recruiting
Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in Chinese patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have HER2 mutations. Although T-DXd is approved and has shown efficacy in clinical trials for NSCLC patients with these mutations, there is limited data on its use outside clinical trial settings in China. This is a non-interventional, observational study where no study drug will be provided or administered by the study team. Participants who have already received T-DXd as part of their routine care, based on their physicians decision, will be enrolled and observed. The study focuses on patients receiving T-DXd as at least a second-line treatment. Participants will be followed for up to approximately two years, during which researchers will collect information on progression-free survival, overall survival, treatment responses, and any treatment-related side effects. Data collection will include assessments by investigators and monitoring of adverse events to evaluate safety and tolerability in a real-world setting.
Actively Recruiting
Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.
1-10 of 22
1